Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/6XY stock hub

FRA/6XY has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/6XYis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.2B

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/6XYFRA/6XY

—

Loading chart…

In the news

Latest news · FRA/6XY

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E22.7

P25 n/aP50 n/aP75 n/a

Trailing P/E15.4

P25 n/aP50 n/aP75 n/a

ROE37.6

P25 n/aP50 n/aP75 n/a

ROIC173.4

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/6XY market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

195

Groups with data

Currency

USD

Showing 195 of 195 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Cayman Islands
Country code	DE
Employees	272
Employees Change	89%
Employees Change Percent	48.63
Enterprise value	EUR 925.6M
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 1.2B
Price	EUR 1.4
Price currency	EUR
Rev Per Employee	494,659.22x
Sic	2836
Symbol	fra/6XY
Website	https://www.harbourbiomed.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	6.5%
EV Earnings	11.9x
EV/EBIT	13.61x
EV/EBITDA	13.21x
EV/FCF	14.1x
EV/Sales	6.94x
FCF yield	5.48%
Forward P/E	22.72x
P/B ratio	3.83x
P/E ratio	15.39x
P/S ratio	8.9x
PE Ratio3 Y	23.86x
PE Ratio5 Y	18.12x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	51.01%
EBITDA Margin	51.65%
FCF margin	48.78%
Gross margin	94.47%
Gross Profit	EUR 127.1M
Gross Profit Growth	38.76%
Gross Profit Growth Q	375.62%
Gross Profit Growth3 Y	29.32%
Gross Profit Growth5 Y	22.57%
Net Income	EUR 77.8M
Net Income Growth	3,187.73%
Net Income Growth Q	1,348.67%
Net Income Growth3 Y	62.46%
Pretax Margin	59.21%
Profit Margin	57.81%
Profit Per Employee	EUR 285,986
ROA	14.08
Roa5y	-7.46
ROCE	19.46
ROE	37.55
Roe5y	-14.6
ROIC	173.4
Roic5y	-256.7

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	55.6%
Cagr3y	94.56%
EPS Growth	2,958.9
EPS Growth Q	1,132.2
EPS Growth3 Y	56.55
FCF Growth	152.67%
FCF Growth3 Y	56.41%
OCF Growth	165.14%
OCF Growth3 Y	56.84%
Revenue Growth	314.63x
Revenue Growth Q	293.5x
Revenue Growth3 Y	29.82x
Revenue Growth5 Y	23.94x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.44
Assets	EUR 426.1M
Cash	EUR 343.3M
Current Assets	EUR 378.1M
Current Liabilities	EUR 73.1M
Debt	EUR 69.6M
Debt EBITDA	EUR 0.98
Debt Equity	EUR 0.22
Debt FCF	EUR 1.06
Equity	EUR 312.7M
Interest Coverage	39.48
Liabilities	EUR 113.4M
Long Term Assets	EUR 48M
Long Term Liabilities	EUR 40.3M
Net Cash	EUR 273.6M
Net Cash By Market Cap	EUR 22.86
Net Cash Growth	203.44%
Net Debt EBITDA	EUR -3.94
Net Debt Equity	EUR -0.88
Net Debt FCF	EUR -4.17
Tangible Book Value	EUR 306.1M
Tangible Book Value Per Share	EUR 0.37

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	5.17
Inventory Turnover	1.99
Net Working Capital	EUR 12.5M
Quick ratio	4.74
Working Capital	EUR 306.3M
Working Capital Turnover	EUR 0.55

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-4.95%
Payout Ratio	0.39%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	55.56%
200-day SMA	1.36
3Y total return	636.84%
50-day SMA	1.38
50-day SMA vs 200-day SMA	50over200
All Time High	2.14
All Time High Change	-34.58%
All Time High Date	2025-09-08
All Time Low	0.1
All Time Low Change	1,350.78%
All Time Low Date	2024-09-10
ATR	0.04
Ch YTD	9.38
High	1.4
High52	2.14
High52 Date	2025-09-08
High52ch	-34.58%
Low	1.4
Low52	0.8
Low52 Date	2025-07-11
Low52ch	75%
Ma50ch	1.16%
Price vs 200-day SMA	2.87%
RSI	46.55
RSI Monthly	66.07
RSI Weekly	52.38
Sharpe ratio	0.69x
Sortino ratio	1.14
Total Return	-4.95%
Tr YTD	9.38
Tr1m	-10.26%
Tr1w	1.45%
Tr3m	21.74%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 68.6M
Operating Income Growth	24.39
Operating Income Growth3 Y	66.04
Operating margin	51.01

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	529,304,992%
Net Borrowing	10,802,187.9
Shares Insiders	7.64%
Shares Institutions	12.47%
Shares Qo Q	7.01%
Shares Yo Y	4.95%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 62.9M
Average Volume	12.5x
Bv Per Share	0.37
CAPEX	EUR -3.6M
Ch1m	-10.26
Ch1w	1.45
Ch1y	55.56
Ch3m	21.74
Ch3y	636.8
Ch6m	-6.04
Change	-2.1%
Change From Open	0
Close	1.43
Days Gap	-2.1
Depreciation Amortization	861,529.4
Earnings Date	2026-08-27
EBIT	EUR 68.6M
EBITDA	EUR 69.5M
EPS	EUR 0.09
F Score	6
FCF	EUR 65.6M
FCF EV Yield	7.09x
Financing CF	134,017,550
Fiscal Year End	December
Founded	2,016
Graham Number	0.86524
Graham Upside	-38.2
Income Tax	EUR 1.1M
Investing CF	-152,472,186
Is Primary Listing	0
Last Earnings Date	2026-03-30
Last Report Date	2025-12-31
Lynch Fair Value	EUR 2.27
Lynch Upside	62.47
Ma150	1.41
Ma150ch	-0.64%
Ma20	1.47
Ma20ch	-4.76%
Net CF	51,131,810
Next Earnings Date	2026-08-27
Open	1.4
P FCF Ratio	18.24
P OCF Ratio	17.28
Ppne	10,456,219.4
Price Date	2026-05-08
Price EBITDA	EUR 17.22
Ptbv Ratio	3.91
Relative Volume	20x
Revenue	134,547,308x
SBC By Revenue	2.04x
Share Based Comp	2,748,436
Tax By Revenue	0.84x
Tax Rate	1.41%
Tr6m	-6.04%
Z Score	4.56

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/6XY pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/6XY stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/6XY?

Insider, institutional, and short-interest positioning.

Institutional ownership

+12.5%

Share of float held by funds and institutions

Insider ownership

+7.6%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+4.9%

Negative means the company is buying back shares.

Technical

FRA/6XY momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

46.5

Neutral momentum band

Price vs 200-day MA

+2.9%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.69

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/6XY

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/6XY stock rating?

fra/6XY is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/6XY analysis?

The full report lives at /stocks/fra/6XY/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/6XY?

The latest report frames fra/6XY around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/6XY page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.